fda tirzepatide compound approval Judge says compounding pharmacies must stop making copies of Zepbound, Mounjaro What Is Compounded Tirzepatide? FDA

262,263 Additionally, substituting dietary SFAs with monounsaturated fatty acids improves nerve function in HFD mice without significantly altering plasma metabolic profiles, suggesting that dietary fats influence neuropathy development

Lifestyle effects on aging and CVD: A spotlight on the nutrient-sensing network

The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)

Wegovy (semaglutide) The STEP UP trial followed 1,407 adults with obesity over 72 weeks

Meanwhile, the reduction of beneficial bacteria (e.g., Bifidobacterium) results in insufficient production of short-chain fatty acids (SCFAs), which not only weakens their anti-inflammatory effects but also loses the inhibitory regulation on glycolysis, further breaking the balance (51, 52)